Results from two Phase 3 studies showed Trumenba (meningococcal group B vaccine; Pfizer) met all 5 co-primary immunogenicity endpoints against diverse meningococcal group B (MenB) strains. The full data has been published in the New England Journal of Medicine.
The two trials involved >7,000 healthy adolescents and young adults aged 10–18 years and 18–25 years, respectively. When given as a 3-dose schedule (Months 0, 2, and 6), Trumenba exhibited immunogenicity against 4 primary MenB strains representing the ones causing invasive disease. There was a high proportion of adolescents (78.8%–90.2%) and young adults (78.9%–89.7%) achieving ≥4-fold increases in hSBA titers after dose 3. Similarly, a high proportion of adolescents (82.7%) and young adults (84.5%) achieved a prespecified hSBA titer for all 4 primary strains (composite response).
Currently, the Centers for Disease Control and Prevention (CDC) recommends routine MenB vaccination for patients aged ≥10 years who are at increased risk. Healthy adolescents and young adults aged 16–23 years may also be vaccinated. The 3-dose Trumenba schedule has been recommended for high-risk individuals whereas the 2-dose schedule is recommended for healthy adolescents and young adults.
Trumenba is available as a suspension comprised of 2 recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B. It is supplied as single-use prefilled syringes in 5- and 10-count packages.
For more information call (800) 438-1985 or visit Trumenba.com.